Ever Supreme Bio Technology (6712) Monthly Revenue

Market: TPEx (OTC) · Industry: Biotech & Medical · 長聖

Ever Supreme Bio Technology (6712) reported revenue of NT$112.1 million for Oct 2026, +0.8% year on year and +1.5% from the previous month. Revenue for Jan–Oct 2026 was NT$891.6 million (+15.2% year on year).

Year-on-year revenue growth: 25+ months in a row. →

In Oct 2026, it ranked No. 69 by revenue among 160 Biotech & Medical companies.

Monthly revenue chart

Oct 2024 NT$99.1 million24/10Nov 2024 NT$123.5 millionDec 2024 NT$127.1 millionJan 2025 NT$56.9 millionFeb 2025 NT$60.2 million25/02Mar 2025 NT$60.9 millionApr 2025 NT$67.5 millionMay 2025 NT$72.5 millionJun 2025 NT$80.9 million25/06Jul 2025 NT$82.2 millionAug 2025 NT$90.5 millionSep 2025 NT$91.1 millionOct 2025 NT$111.1 million25/10Nov 2025 NT$125 millionDec 2025 NT$128 millionJan 2026 NT$58.2 millionFeb 2026 NT$62.2 million26/02Mar 2026 NT$70.1 millionApr 2026 NT$85.2 millionMay 2026 NT$90.6 millionJun 2026 NT$93.9 million26/06Jul 2026 NT$99.2 millionAug 2026 NT$109.6 millionSep 2026 NT$110.5 millionOct 2026 NT$112.1 million26/10

Hover over (or tap) a bar to see that month’s revenue.

Monthly revenue history

MonthRevenueYoYMoM
Oct 2026NT$112.1 million+0.8%+1.5%
Sep 2026NT$110.5 million+21.3%+0.8%
Aug 2026NT$109.6 million+21.1%+10.5%
Jul 2026NT$99.2 million+20.7%+5.7%
Jun 2026NT$93.9 million+16.1%+3.6%
May 2026NT$90.6 million+25.0%+6.3%
Apr 2026NT$85.2 million+26.2%+21.6%
Mar 2026NT$70.1 million+15.1%+12.7%
Feb 2026NT$62.2 million+3.4%+6.9%
Jan 2026NT$58.2 million+2.4%-54.5%
Dec 2025NT$128 million+0.7%+2.4%
Nov 2025NT$125 million+1.3%+12.5%
Oct 2025NT$111.1 million+12.2%+22.0%
Sep 2025NT$91.1 million+1.2%+0.6%
Aug 2025NT$90.5 million+3.1%+10.1%
Jul 2025NT$82.2 million+17.1%+1.7%
Jun 2025NT$80.9 million+30.2%+11.6%
May 2025NT$72.5 million+20.5%+7.3%
Apr 2025NT$67.5 million+20.5%+10.9%
Mar 2025NT$60.9 million+10.6%+1.2%
Feb 2025NT$60.2 million+9.6%+5.8%
Jan 2025NT$56.9 million+6.3%-55.3%
Dec 2024NT$127.1 million+56.8%+2.9%
Nov 2024NT$123.5 million+41.0%+24.6%
Oct 2024NT$99.1 million+13.2%+10.1%

Jan–Oct 2026 cumulative: NT$891.6 million (+15.2% YoY)

History covers months since this site began collecting, plus prior-month and prior-year figures in each release. It grows every month.

Other Biotech & Medical companies

Compare with peers: Ever Supreme Bio Technology vs PEC / Ever Supreme Bio Technology vs Lotus Pharm / Ever Supreme Bio Technology vs Bora

CompanyRevenueYoY
PEC6446NT$2.84 billion+102.0%
Lotus Pharm1795NT$2.13 billion-22.5%
Bora6472NT$1.99 billion+15.9%
Great Tree Pharmacy6469NT$1.67 billion+1.5%
EXCELSIOR4104NT$1.02 billion+38.6%
PEGAVISION6491NT$793 million+13.0%
Synmosa Biopharma4114NT$766.6 million+41.2%
Y.S.H.3705NT$749.4 million+4.4%

See also

← All Taiwan listed & OTC companies

Sources: Taiwan Stock Exchange, monthly revenue of listed companies (Government Open Data Platform); Taipei Exchange, monthly revenue of OTC companies (TPEx OpenAPI); historical months from MOPS. Amounts in New Taiwan dollars. Changes calculated by this site from the source figures. Not investment advice. Updated: 2026-11-16